ClinicalTrials.gg
Active, not recruitingNCT07316764Updated Oct 6, 2026

Eccentric Cycling in Multiple Sclerosis Rehabilitation

An interventional study of Eccentric training and Concentric training in Multiple Sclerosis, Rehabilitation and Neuro-Degenerative Disease, sponsored by University of Liege. Active, not recruiting at 1 site in Belgium. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by University of Liege · Not applicable, Interventional, and Treatment

How we know

Updated Oct 6, 2026Eligibility revisedPrimary outcomes revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 157 studies in Multiple Sclerosis with a site in Belgium — 14 open to participants now, 30 under way, 10 of them phase 3. Multiple Sclerosis · Belgium.

Planned enrollment
96th of 132
60 · median 163
Started
2026
with 4 others
No phase
47 of 157
5 open now
Primary completion
2026-12
later than 11 of 29 live
Registered
153rd of 157
by date

Among the 157 studies in Multiple Sclerosis with a site in Belgium, this one is the 96th largest by planned enrollment of the 132 interventional ones that give a count, is one of 5 that started in 2026, is one of 47 with no phase, reaches primary completion later than 11 of the 29 other live ones, and was the 153rd registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

14 of the 157 studies in Multiple Sclerosis with a site in Belgium are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 157 studies in Multiple Sclerosis with a site in Belgium, or all of them as a file.
02

Study summary

The project aims to optimise functional rehabilitation programmes for people with multiple sclerosis.

Investigators are proposing eccentric cycling as a new exercise modality for treating these patients.

Based on previous results in healthy subjects, investigators will attempt to define the optimal parameters of this new modality (in terms of duration, intensity, frequency, etc.).

Investigators also aim to demonstrate the effectiveness of this training (compared to conventional training) in improving muscle function, functional capacity, perception of chronic fatigue, quality of life, physical condition, and neurological and cognitive function.

Read the detailed description

Our study will focus on multiple sclerosis. For each pathology included, a "control" group will consist of patients undergoing a traditional rehabilitation program combined with a concentric cycling session. An experimental group ("eccentric rehabilitation") will consist of patients enrolled in an eccentric ergocycle training protocol paired with standard rehabilitation. In practice, a portion of the classical rehabilitation program will be replaced by either concentric or eccentric cycling, for a maximum duration of 30 minutes. Based on a preliminary study conducted in healthy subjects, a review of the existing literature, and a sample size calculation performed by the Biostatistics Department of the University Hospital of Liège, investigators aim to recruit 60 to 80 subjects per pathology (details in the appendix). Participation of pregnant women is permitted.

Type of Study

This is a prospective interventional study conducted longitudinally, with all subjects evaluated over the same time period (2025-2027). The study will take place at the Sart-Tilman sites (Blanc-Gravier, Exercise Physiology Unit) or at the CNRF in Fraiture-en-Condroz, depending on participant preference.

Neurological Pathologies Inclusion criteria

Participants must:

present with one of the following neurological disorders: Parkinson's disease or multiple sclerosis.

I. Eccentric Rehabilitation Program

Given the increasing clinical interest in eccentric contraction modalities for chronic diseases, a semi-recumbent eccentric ergometer has been specifically designed for clinical use. Patient installation on this device is safe and easily achievable, and the semi-recumbent position provides additional comfort during exercise. The ergometer allows secure workload control via visual feedback powered by dedicated software. The device can be transported between sites (Sart-Tilman - Fraiture - Esneux).

Experimental Protocol

This experimental study aims to establish and compare the effects of an eccentric cycling training protocol versus a traditional concentric cycling protocol performed on an ergometric bicycle. Subjects will be randomly allocated (stratified by sex and disease stage) into one of the two experimental groups. Randomization will be conducted by Mr. Benoît Vandenbroeck after encoding the relevant data in a table and assigning subjects within each stratum using random distribution.

Ambulatory participants will undergo a 2-week evaluation period followed by a 12-week training program consisting of two sessions per week, for a total of 28 sessions. In-hospitalisation participants will undergo a 1-week evaluation period (3 sessions), followed by 12 cycling training sessions and a 3 last sessions of evaluation, over a 4-week period, for a total of 18 sessions. Sessions will take place either at the Neurological and Functional Rehabilitation Center in Fraiture-en-Condroz (CNRF) or at Blanc-Gravier (Sart-Tilman), according to participant preference. Training sessions (eccentric or concentric) will last a maximum of 30 minutes. For participants already enrolled in a rehabilitation program at the CNRF, part of their traditional session will be replaced by the cycling training.

The unusual nature of eccentric training may induce mild delayed-onset muscle soreness (DOMS), including pain and stiffness, appearing 24-48 hours after exercise. These symptoms are transient, and symptomatic treatments (analgesics, stretching, ice) are not permitted.

Multiple variables will be assessed before, during, and after the intervention period to quantify potential effects of each training protocol and allow direct comparison.

Description of Study Phases

The study consists of 5 phases over a 12-week period for ambulatory participants and a 4-week period for in-hospitalisation participants (see appendix):

Phase 0: Baseline Testing

Out participants : Measurements will be collected 5-7 days before and 7-14 days after the training period to monitor longitudinal changes and evaluate the impact of the protocols on body composition and functional capacity.

In participants : Measurements will be collected the fisrt and lest (4th) week of the training program.

Eccentric Ergocycle Training Protocol Phase 1: Familiarization (4 weeks)

Out participants:

Two sessions per week for four weeks.

In participants:

Three sessions per week for two weeks. The main objective is to familiarize subjects with eccentric cycling and its specific neuromuscular demands, thus limiting potential muscle damage. Duration and intensity will gradually increase. To progress to the training phase, subjects must maintain an average power output within ±10% of their target theoretical power during the final familiarization session. If needed, one to two additional weeks of familiarization may be added. Beyond this point, participants unable to meet the criteria will be withdrawn from the study.

Phase 2: Training (Part 1 - 4 weeks)

Out:

These four weeks establish the first phase of training, with predefined duration and intensity levels.

In:

Two weeks with three training a week, with predefined duration and intensity levels.

Phase 3: Training (Part 2 - 4 weeks)

Out:

An additional four weeks are included, based on evidence showing greater benefits after 8-12 weeks of training. Intensity will be increased during this phase.

In:

An additional week (with three sessions) is included with an increased intensity.

Throughout the 12-week training period, temporal progression and identification of potential physiological adaptations will be monitored.

Phase 4: Final Testing

Out:

Participants will return to the laboratory twice to repeat the baseline assessments. These tests will be performed 7-10 days after the final training session to ensure adequate muscle recovery.

In:

Participants will take the three last evaluation sessions during the last (4th) week of the program.

03

Conditions studied

  • Multiple Sclerosis
  • Rehabilitation
  • Neuro-Degenerative Disease
  • Neurorehabilitation

Browse trials for

Keywords

  • eccentric cycling
  • multiple sclerosis
  • eccentric training
  • neurorehabilitation
  • physical therapy
  • neuro-degenerative disease
04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple sclerosis
  • Multiple sclerosis: EDSS score \< 7
  • Age under 75 years
  • Stable disease state
  • Written medical clearance authorizing participation
  • Legal adult status
  • Written , with demonstrated understanding of the consent form (via a few specific questions)
  • Ability to mobilize independently (e.g., transfers, walking)

Exclusion criteria

Exclusion Criteria:

  • One or more to physical activity
  • Significant comorbidities
  • Active flare-up
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Eccentric group

    Other: Eccentric training

  • Active comparator
    Concentric group

    Other: Concentric training

Interventions

  • OtherEccentric training

    Eccentric cycling training

  • OtherConcentric training

    Concentric cycling training

06

What researchers measure

Primary outcomes

  1. Maximal Isometric Force

    Maximal Isometric Force (in Newton-meters - Nm) of the quadriceps will be measured using a fixed dynamometer (Kinvent), at 90 degrees of knee flexion.

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  2. Walking distance

    6 minutes walking test and 2 minutes walking test will be performed to measure the walking capacities (in meters) of participants.

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  3. Glial Fibrillary Acidic Protein (GFAP)

    Blood samples will be collected to analyse GFAP concentration. This specific biomarker reflect chronic astrocytic activation, glial scarring, and track Progression Independent of Relapse Activity (PIRA) as well as diffuse, underlying neurodegeneration.

    Time frame: At baseline and endline of intervention (Week 1 and 4)

  4. Neurofilament Light Chain (NfL)

    NfL is a structural component of nerve fibers (axons). Elevated levels in the blood reflect acute axonal injury, focal inflammatory activity, and help predict upcoming relapses.

    Time frame: At baseline and endline of intervention (week 1 and 4)

Secondary outcomes

  1. Handgrip strength

    Handgrip strength (in kilograms) will be measured using a handheld dynamometer.

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  2. Spasticity

    Spasticity will be evaluated using the Tardieu's scale of spasticity (expressed in arbitrary unit). This scale ranges from 0 (no resistance) to 4 (immobile)

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  3. Timed up and go

    The TUAG (in seconds) will be used to evaluate lower limb functional capacity

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  4. Neurocognitive capacity

    Neurocognitive capacity will be evaluated using a combinaison of Tests of Attentional Performance battery (TAP battery)

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  5. Berg Balance Scale

    The balance test will be used to evaluate balance capacity (expressed in arbitrary unit). This scale ranges from 0 (High fall risk) to 56 (no fall risk)

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  6. Five time sit to stand test

    The sit to stand test (in seconds) will be performed to measure lower limb functional capacity

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  7. Maximal aerobic power

    Maximal aerobic power (in Watts) will be evaluated by performing a Cardiopulmonary Exercise Test on an ergocycle.

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  8. Maximal oxygen consumption

    Oxygen consumption (in milliliter per minute per kilogram ) will be evaluated by performing a cardiopulmonary exercise test on an ergometer.

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  9. Fatigue

    Fatigue will be evaluated using the modified fatigue impact scale (MFIS) (expressed in arbitrary unit). This scale present different item that should be ranged from 0 (never) to 4 (always). We will collect the physical aspect with a maximal score ranginig from 0 (no fatigue) to 36 (exhausted)

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  10. Multiple Sclerosis Quality of Life-54

    Quality of life will be evaluated using the Multiple Sclerosis Quality of Life-54 (MSQoL-54). This scale will be expressed in percent.

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  11. Maximal heart rate

    Maximal heart brate (in beats per minute) will be measured by performing a cardiopulmonary exercise test on an ergocycle.

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  12. Posturographic data

    K-Force Plates (Kinvent) will allow us to assess both static and dynamic balance in order to objectively evaluate postural control, stability, and asymmetries.

    Time frame: At baseline and endline of intervention (week 1 and 4)

Other outcomes

  1. Height

    Height will me measured and expressed in centimeters.

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  2. Weight

    Weight in kilograms will be measured using a Tanita scale.

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  3. Body fat percentage

    Body fat percentage (in percent) will be measured using a Tanita scale.

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  4. Body mass index

    BMI (in kilograms per square meters) will be measured using the height and the weight (H/W\^2).

    Time frame: At baseline and endline of intervention (Week 1 and 14)

  5. Heart rate

    Heart rate (in percent of max heart rate) will be analyzed during each training session

    Time frame: Throughout the entire intervention (week 2 to week 13)

  6. Rating of perceived exertion

    RPE (in arbitrary unit) will be evaluated using the Borg scale after each training session. Borg scale ranges from 6 (no exertion) to 20 (extremely hard).

    Time frame: Throughout the entire intervention (week 2 to week 13)

  7. Mental demand

    Mental demand of the training (in arbitrari unit) will be evaluated using a modified Borg scale after each training session. Modified Borg scale ranges from 0 (no exertion) to 10 (extremely hard).

    Time frame: Throughout the entire intervention (week 2 to week 13)

  8. Muscle soreness

    Muscle soreness (in arbitrary unit) will be evaluated using a visual analog scale before each training session. This scale ranges from 0 (no pain) to 10 (worst pain possible).

    Time frame: Throughout the entire intervention (week 2 to week 13)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 9 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2025
First posted
Jan 5, 2026
StartActual
Mar 27, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Jul 31, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Liege University · Liège, Belgium
Show 1 removed
  • Liege University · Liège, Belgium
Oct 6, 2026
Eligibility
1 exclusion criterion removed
What changed in the criteria
Exclusion criteria
  • RemovedCurrent hospitalization or undergoing changes in medication
Oct 6, 2026
Primary outcomes
2 added
What changed in the outcomes
  • AddedGlial Fibrillary Acidic Protein (GFAP)Time frame: At baseline and endline of intervention (Week 1 and 4)
  • AddedNeurofilament Light Chain (NfL)Time frame: At baseline and endline of intervention (week 1 and 4)
Oct 6, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedPosturographic dataTime frame: At baseline and endline of intervention (week 1 and 4)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    1 site added, 1 site removed
    Show site
    • Liege University · Liège, Belgium
    Show 1 removed
    • Liege University · Liège, Belgium
    Eligibility 1 exclusion criterion removed
    What changed in the criteria
    Exclusion criteria
    • RemovedCurrent hospitalization or undergoing changes in medication
    Primary outcomes 2 added
    What changed in the outcomes
    • AddedGlial Fibrillary Acidic Protein (GFAP)Time frame: At baseline and endline of intervention (Week 1 and 4)
    • AddedNeurofilament Light Chain (NfL)Time frame: At baseline and endline of intervention (week 1 and 4)
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedPosturographic dataTime frame: At baseline and endline of intervention (week 1 and 4)
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07316764
Collaborators
University Hospital Sart Tilman, Liege
Responsible party
Vandenbroeck Benoit (Physiotherapist, University of Liege) — Principal investigator
First posted
Jan 5, 2026
Start date
Mar 27, 2026
Primary completion
Dec 30, 2026 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Stéphanie HODY, PhD
study chair · Department of Physical Activity and Rehabilitation Sciences, University of Liege and University Hospital of Liege, Liege, Belgium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion